These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 12393655)

  • 1. Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection.
    Savoldo B; Huls MH; Liu Z; Okamura T; Volk HD; Reinke P; Sabat R; Babel N; Jones JF; Webster-Cyriaque J; Gee AP; Brenner MK; Heslop HE; Rooney CM
    Blood; 2002 Dec; 100(12):4059-66. PubMed ID: 12393655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical effects of infusing anti-Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes into patients with severe chronic active EBV infection.
    Hagihara M; Tsuchiya T; Hyodo O; Ueda Y; Tazume K; Masui A; Kanemura A; Yoshiba F; Takashimizu S; Matzusaki S; Kato S; Hotta T
    Int J Hematol; 2003 Jul; 78(1):62-8. PubMed ID: 12894853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes.
    Comoli P; Pedrazzoli P; Maccario R; Basso S; Carminati O; Labirio M; Schiavo R; Secondino S; Frasson C; Perotti C; Moroni M; Locatelli F; Siena S
    J Clin Oncol; 2005 Dec; 23(35):8942-9. PubMed ID: 16204009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of autologous Epstein-Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipients.
    Savoldo B; Goss J; Liu Z; Huls MH; Doster S; Gee AP; Brenner MK; Heslop HE; Rooney CM
    Transplantation; 2001 Sep; 72(6):1078-86. PubMed ID: 11579304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful control of Epstein-Barr virus (EBV)-infected cells by allogeneic nonmyeloablative stem cell transplantation in a patient with the lethal form of chronic active EBV infection.
    Uehara T; Nakaseko C; Hara S; Harima A; Ejiri M; Yokota A; Saito Y; Nishimura M
    Am J Hematol; 2004 Aug; 76(4):368-72. PubMed ID: 15282671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful in vitro generation of Epstein-Barr virus-specific cytotoxic T lymphocytes from severe chronic active EBV patients.
    Hagihara M; Tsuchiya T; Ueda Y; Masui A; Gansuvd B; Munkhbat B; Inoue H; Hyodo O; Ando K; Kato S; Hotta T
    Med Microbiol Immunol; 2001 Apr; 189(3):137-45. PubMed ID: 11388611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adoptive transfer of Epstein-Barr virus-specific cytotoxic T-lymphocytes for the treatment of angiocentric lymphomas.
    Cho HI; Hong YS; Lee MA; Kim EK; Yoon SH; Kim CC; Kim TG
    Int J Hematol; 2006 Jan; 83(1):66-73. PubMed ID: 16443556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas.
    Liu Z; Savoldo B; Huls H; Lopez T; Gee A; Wilson J; Brenner MK; Heslop HE; Rooney CM
    Recent Results Cancer Res; 2002; 159():123-33. PubMed ID: 11785836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV-induced B cell lymphoproliferations in xenografted C.B-17 scid/scid mice.
    Lacerda JF; Ladanyi M; Louie DC; Fernandez JM; Papadopoulos EB; O'Reilly RJ
    J Exp Med; 1996 Mar; 183(3):1215-28. PubMed ID: 8642263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Establishment and characterization of a bank of cytotoxic T lymphocytes for immunotherapy of epstein-barr virus-associated diseases.
    Wilkie GM; Taylor C; Jones MM; Burns DM; Turner M; Kilpatrick D; Amlot PL; Crawford DH; Haque T
    J Immunother; 2004; 27(4):309-16. PubMed ID: 15235392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I-II trial to examine the toxicity of CMV- and EBV-specific cytotoxic T lymphocytes when used for prophylaxis against EBV and CMV disease in recipients of CD34-selected/T cell-depleted stem cell transplants.
    Lucas KG; Sun Q; Burton RL; Tilden A; Vaughan WP; Carabasi M; Salzman D; Ship A
    Hum Gene Ther; 2000 Jul; 11(10):1453-63. PubMed ID: 10910142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of Epstein-Barr virus nuclear antigen 1, 3 and lytic antigen BZLF1 peptide pools allows fast and efficient stimulation of Epstein-Barr virus-specific T cells for adoptive immunotherapy.
    Wang Y; Aïssi-Rothe L; Virion JM; De Carvalho Bittencourt M; Ulas N; Audonnet S; Salmon A; Clement L; Venard V; Jeulin H; Stoltz JF; Decot V; Bensoussan D
    Cytotherapy; 2014 Jan; 16(1):122-34. PubMed ID: 24094498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins.
    Bollard CM; Gottschalk S; Torrano V; Diouf O; Ku S; Hazrat Y; Carrum G; Ramos C; Fayad L; Shpall EJ; Pro B; Liu H; Wu MF; Lee D; Sheehan AM; Zu Y; Gee AP; Brenner MK; Heslop HE; Rooney CM
    J Clin Oncol; 2014 Mar; 32(8):798-808. PubMed ID: 24344220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients.
    Heslop HE; Slobod KS; Pule MA; Hale GA; Rousseau A; Smith CA; Bollard CM; Liu H; Wu MF; Rochester RJ; Amrolia PJ; Hurwitz JL; Brenner MK; Rooney CM
    Blood; 2010 Feb; 115(5):925-35. PubMed ID: 19880495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Adoptive transfer of Epstein-Barr virus-specific T-lymphocytes in chronic active Epstein-Barr infection].
    Babel N; Hammer MH; Reinke P
    Dtsch Med Wochenschr; 2003 Mar; 128(11):548-50. PubMed ID: 12635027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs).
    Savoldo B; Goss JA; Hammer MM; Zhang L; Lopez T; Gee AP; Lin YF; Quiros-Tejeira RE; Reinke P; Schubert S; Gottschalk S; Finegold MJ; Brenner MK; Rooney CM; Heslop HE
    Blood; 2006 Nov; 108(9):2942-9. PubMed ID: 16835376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment and characterization of the cytolytic T lymphocyte response against Epstein-Barr virus in patients with non-Hodgkin's lymphoma after autologous peripheral blood stem cell transplantation.
    Nolte A; Buhmann R; Straka C; Emmerich B; Hallek M
    Bone Marrow Transplant; 1998 May; 21(9):909-16. PubMed ID: 9613783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease.
    Khanna R; Bell S; Sherritt M; Galbraith A; Burrows SR; Rafter L; Clarke B; Slaughter R; Falk MC; Douglass J; Williams T; Elliott SL; Moss DJ
    Proc Natl Acad Sci U S A; 1999 Aug; 96(18):10391-6. PubMed ID: 10468618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ex vivo generation of effective Epstein-Barr virus (EBV)-specific CD8+ cytotoxic T lymphocytes from the peripheral blood of immunocompetent Epstein Barr virus-seronegative individuals.
    Metes D; Storkus W; Zeevi A; Patterson K; Logar A; Rowe D; Nalesnik MA; Fung JJ; Rao AS
    Transplantation; 2000 Nov; 70(10):1507-15. PubMed ID: 11118098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics of human EBV-specific cytotoxic T lymphocytes utilized for adoptive immunotherapy of EBV-induced lymphoproliferations in xenografted SCID mice.
    Lacerda JF; O'Reilly RJ
    Ann Oncol; 1997; 8 Suppl 2():137-40. PubMed ID: 9209657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.